Dual-loaded, long-term sustained drug releasing and thixotropic hydrogel for localized chemotherapy of cancer

被引:24
作者
Cao, Han [1 ]
Duan, Yu [1 ]
Lin, Qinrui [1 ,2 ]
Yang, Yuhong [2 ]
Gong, Zuguang [1 ]
Zhong, Yiming [3 ,4 ]
Chen, Xin [1 ]
Shao, Zhengzhong [1 ]
机构
[1] Fudan Univ, Dept Macromol Sci, State Key Lab Mol Engn Polymers, Adv Mat Lab, Shanghai 200438, Peoples R China
[2] Fudan Univ, Res Ctr Anal & Measurement, Shanghai, Peoples R China
[3] Curtin Univ, Fuels & Energy Technol Inst, Perth, WA, Australia
[4] Curtin Univ, Dept Chem Engn, Perth, WA, Australia
基金
中国国家自然科学基金;
关键词
AMPLITUDE OSCILLATORY SHEAR; SILK FIBROIN; CURCUMIN NANOFORMULATIONS; INJECTABLE HYDROGELS; MULTIDRUG-RESISTANCE; DELIVERY; DOXORUBICIN; NMR; NANOPARTICLES; NANOMEDICINE;
D O I
10.1039/c9bm00540d
中图分类号
TB3 [工程材料学]; R318.08 [生物材料学];
学科分类号
0805 ; 080501 ; 080502 ;
摘要
Localized cancer chemotherapy is an intra-tumoral treatment and can effectively prevent locoregional recurrence. In this study, we proposed an environmentally-friendly method to load both hydrophilic (Doxorubicin, Dox) and hydrophobic (Curcumin, Cur) drugs into one hydrogel. The hydrogel was composed of two naturally derived polymers, regenerated silk fibroin (RSF) and hydroxypropylcellulose (HPC), and was endowed with thixotropic properties because of its differently crystalized beta-sheet region. Moreover, by taking advantage of the specific interactions between Cur and the beta-sheet region in the hydrogel, the solubility and stability of the hydrophobic Cur were dramatically improved. Because the multiple interactions between the two drugs and the hydrogel lead to different release profiles for Cur and Dox, the dual-drug loaded hydrogel presented superior long-term sustained antitumor efficacy compared with the free drug and the Dox single-loaded hydrogel. The dual-drug loaded hydrogel exhibited an enhanced therapeutic effect and a reversal of multiple drug resistance (MDR) to Dox. Moreover, by investigating the mechanism of the thixotropicity of our hydrogel, we concluded that this property results from the slipping and deformation of beta-sheet enriched domains as well as the destruction/reconstruction of weak crosslinks.
引用
收藏
页码:2975 / 2985
页数:11
相关论文
共 50 条
[41]   Phase III Randomized Trial of Dose Intensive Neoadjuvant Chemotherapy with or Without G-CSF in Locally Advanced Breast Cancer: Long-Term Results [J].
Arun, Banu K. ;
Dhinghra, Kapil ;
Valero, Vicente ;
Kau, Shu-Wan ;
Broglio, Kristine ;
Booser, Daniel ;
Guerra, Laura ;
Yin, Guosheng ;
Walters, Ronald ;
Sahin, Aysegul ;
Ibrahim, Nuhad ;
Buzdar, Aman U. ;
Frye, Debbie ;
Sneige, Nour ;
Strom, Eric ;
Ross, Merrick ;
Theriault, Richard L. ;
Vadhan-Raj, Saroj ;
Hortobagyi, Gabriel N. .
ONCOLOGIST, 2011, 16 (11) :1527-1534
[42]   Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: The M.D. Anderson experience, with long-term follow-up [J].
Ibrahim, NK ;
Buzdar, AU ;
Asmar, L ;
Theriault, RL ;
Hortobagyi, GN .
ANNALS OF ONCOLOGY, 2000, 11 (12) :1597-1601
[43]   Long-term sustained-released in situ gels of a water-insoluble drug amphotericin B for mycotic arthritis intra-articular administration: preparation, in vitro and in vivo evaluation [J].
Shan-Bin, Guo ;
Yue, Tian ;
Ling-Yan, Jian .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2015, 41 (04) :573-582
[44]   Long-Term Outcomes in Stage IIIB Breast Cancer Patients Who Achieved Less Than a Pathological Complete Response (<pCR) After Primary Chemotherapy [J].
Ionta, Maria Teresa ;
Atzori, Francesco ;
Deidda, Maria Cristina ;
Pusceddu, Valeria ;
Palmeri, Sergio ;
Frau, Barbara ;
Murgia, Monica ;
Barca, Michela ;
Minerba, Luigi ;
Massidda, Bruno .
ONCOLOGIST, 2009, 14 (11) :1051-1060
[45]   Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival A Randomized Clinical Trial [J].
Lambertini, Matteo ;
Boni, Luca ;
Michelotti, Andrea ;
Gamucci, Teresa ;
Scotto, Tiziana ;
Gori, Stefania ;
Giordano, Monica ;
Garrone, Ornella ;
Levaggi, Alessia ;
Poggio, Francesca ;
Giraudi, Sara ;
Bighin, Claudia ;
Vecchio, Carlo ;
Sertoli, Mario Roberto ;
Pronzato, Paolo ;
Del Mastro, Lucia .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (24) :2632-2640
[46]   Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314 NCT02177695) ; [J].
Flaig, Thomas W. ;
Tangen, Catherine M. ;
Daneshmand, Siamak ;
Alva, Ajjai Shivaram ;
Lucia, M. Scott ;
McConkey, David James ;
Theodorescu, Dan ;
Goldkorn, Amir ;
Milowsky, Matthew I. ;
Bangs, Rick ;
MacVicar, Gary R. ;
Bastos, Bruno R. ;
Fowles, Jared S. ;
Gustafson, Daniel L. ;
Plets, Melissa ;
Thompson Jr, Ian M. ;
Lerner, Seth P. .
EUROPEAN UROLOGY, 2023, 84 (03) :341-347
[47]   Heparin-modified graphene oxide loading anti-cancer drug and growth factor with heat stability, long-term release property and lower cytotoxicity [J].
Wu, Ting ;
Zhang, Bin ;
Liang, Yuanyuan ;
Liu, Tao ;
Bu, Jinyan ;
Lin, Lixing ;
Wu, Zhimin ;
Liu, Hongxi ;
Wen, Shuiping ;
Tan, Shaozao ;
Cai, Xiang .
RSC ADVANCES, 2015, 5 (102) :84334-84342
[48]   Risk prediction model for long-term heart failure incidence after epirubicin chemotherapy for breast cancer - A real-world data-based, nationwide classification analysis [J].
Fogarassy, Gyorgy ;
Vathy-Fogarassy, Agnes ;
Kenessey, Istvan ;
Kasler, Miklos ;
Forster, Tamas .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2019, 285 :47-52
[49]   Long-Term Outcomes of S-1 Combined With Low-Dose Docetaxel as Neoadjuvant Chemotherapy (N-1 Study, Phase II Trial) in Patients With Breast Cancer [J].
Sasa, Soichiro ;
Inoue, Hiroaki ;
Nakagawa, Misako ;
Toba, Hiroaki ;
Goto, Masakazu ;
Okumura, Kazumasa ;
Misaki, Mariko ;
Inui, Tomohiro ;
Yukishige, Sawaka ;
Nishisho, Aya ;
Hino, Naoki ;
Kanematsu, Miyuki ;
Bando, Yoshimi ;
Uehara, Hisanori ;
Tangoku, Akira ;
Takizawa, Hiromitsu .
CLINICAL BREAST CANCER, 2024, 24 (05) :e350-e359.e2
[50]   Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Long-term results of a European organization for research and treatment of cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone [J].
Kurth, K ;
Tunn, U ;
Ay, R ;
Schroder, FH ;
PavoneMacaluso, M ;
Debruyne, F ;
TenKate, F ;
DePauw, M ;
Sylvester, R ;
Essed, E ;
Caubergh, RV ;
Hoekstra, JW ;
deVoogt, HJ ;
Newling, DWW ;
deReijke, TM ;
Mensink, HJA ;
Groen, JM ;
Jakse, G ;
Leisinger, HJ ;
Richards, B ;
Adib, RA ;
Robinson, M ;
Denis, L ;
Bouffioux, C ;
Schulman, C ;
Carpentier, PJ .
JOURNAL OF UROLOGY, 1997, 158 (02) :378-384